Skip to main content
NCBI home page
Nuclear Medicine and Molecular Imaging logoLink to Nuclear Medicine and Molecular Imaging
. 2015 Aug 21;50(2):180–182. doi: 10.1007/s13139-015-0357-x

Detection of Synchronous Parathyroid Adenoma and Breast Cancer with 18F-Fluorocholine PET-CT

Wessel MCM Vorselaars 1, Wouter P Kluijfhout 1, Menno R Vriens 1, Carmen C van der Pol 1, Inne HM Borel Rinkes 1, Gerlof D Valk 2, Bart de Keizer 3,✉
PMCID: PMC4870458  PMID: 27275374

A 71-year-old woman was referred to our tertiary care center for evaluation of asymptomatic recurrence of primary hyperparathyroidism. As per our protocol, the patient underwent neck/mediastinum 18F-fluorocholine (FCH) positron emission tomography-computed tomography (PET-CT) for localization. In our institution, FCH PET-CT is performed in patients with hyperparathyroidism and negative conventional imaging [1]. FCH PET-CT is a promising new imaging modality for detection of hyperfunctioning parathyroid glands [2, 3]. Thirty minutes after injection of 139 MBq (3.8 mCi), the PET-CT images showed a focal uptake (SUVmax = 1.8) at the lower anterior neck, level VI, anterior to the right common carotid artery (Fig. 1a-f), suspicious for parathyroid adenoma. Additionally, it showed a second focal uptake (SUVmax = 2.5) in a nodal structure measuring 1.2 cm, within the outer lower quadrant of the right breast (Fig. 2a-f). No other pathological uptake was seen. On the subsequent ultrasound (US) of the breast, there was an area of microcalcifications seen with no definite abnormal lesion. US of the axilla was negative for any suspicious lesions. Mammography showed a blurry 1.3-cm mass without clear boarders and microcalcifications within relatively dense fibro-glandular tissue (BI-RADS IV). US-guided core biopsy showed papillary carcinoma. Pathological examination after breast-conserving surgery revealed papillary breast cancer of 1.0 cm, staged pT1N0. The location of the cancer corresponded with that indicated by FCH PET-CT. Due to the finding of breast cancer, surgery for primary hyperparathyroidism was postponed.

Fig. 1.

Fig. 1

Open in a new tab

18F-Fluorocholine PET-CT of the neck/mediastinum: axial (a-c) and coronal (d-f) PET, CT and fused PET-CT images showing a focal uptake (SUVmax = 1.8) at the lower anterior neck, level VI, anterior to the right common carotid artery, suggesting parathyroid adenoma

Fig. 2.

Fig. 2

Open in a new tab

18F-Fluorocholine PET-CT of the neck/mediastinum: axial (a-c) and coronal (d-f) PET, CT and fused PET-CT images showing an additional focal uptake (SUVmax = 2.5) in a nodal structure of 1.2 cm located in the lateral lower quadrant of the right breast

Currently, mammography and US are considered the standard of care in the preoperative workup of breast cancer [4]. Multiple other imaging modalities, including positron emission mammography (PEM) with a variety of radionuclide tracers as well as magnetic resonance imaging (MRI), are currently under investigation [5–7]. Breast cancer has previously been found to have increased uptake of choline [8]. Therefore, the use of 11C-choline PET/CT has been used to accurately localize these malignant tumors [9]. One major drawback is that the half-life of 11C-methionine is only 20 min. This requires on-site production of the tracer to be used in the study, thereby strongly limiting its clinical applicability. The half-life of FCH is 110 min, enabling off-site production and distribution, making it much more practical to use as an imaging modality in this context [10]. Furthermore, FCH is already being used in the evaluation of prostate cancer and is therefore more widely available than other radiotracers [11, 12].

As can be seen in the case presented, high FCH uptake was seen in a small breast cancer. Due to its favorable half-life and wide availability by its use as a localization technique for patients with prostate cancer and complicated hyperparathyroidism, FCH PET-CT may be a new promising modality in the imaging of breast cancer.

Acknowledgments

Conflict of interest

W.M.C.M. Vorselaars, W.P. Kluijfhout, M.R. Vriens, C.C. van derPol, I.H.M. Borel Rinkes, G.D. Valk and B. de Keizer declare that they have no conflict of interest.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  • 1.Kluijfhout WP, Vorselaars WM, Vriens MR, et al. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. Eur J Radiol. 2015 doi: 10.1016/j.ejrad.2015.05.024. [DOI] [PubMed] [Google Scholar]
  • 2.Michaud L, Burgess A, Huchet V, et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99:4531–4536. doi: 10.1210/jc.2014-2821. [DOI] [PubMed] [Google Scholar]
  • 3.Lezaic L, Rep S, Sever MJ, et al. 18F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41:2083–2089. doi: 10.1007/s00259-014-2837-0. [DOI] [PubMed] [Google Scholar]
  • 4.Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi7–vi23. doi: 10.1093/annonc/mdt284. [DOI] [PubMed] [Google Scholar]
  • 5.Calderella C, Treglia G, Giordano A. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. Clin Breast Cancer. 2014;14:241–248. doi: 10.1016/j.clbc.2013.12.004. [DOI] [PubMed] [Google Scholar]
  • 6.Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307:1394–1404. doi: 10.1001/jama.2012.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dorrius MD, de Vries EF, Slart RH, et al. Breast cancer: a new imaging approach as an addition to existing guidelines. Eur J Nucl Med Mol Imaging. 2015;42:813–817. doi: 10.1007/s00259-015-3032-7. [DOI] [PubMed] [Google Scholar]
  • 8.Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004;64:4270–4276. doi: 10.1158/0008-5472.CAN-03-3829. [DOI] [PubMed] [Google Scholar]
  • 9.Contractor KB, Kenny LM, Stebbing J, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009;15:5503–5510. doi: 10.1158/1078-0432.CCR-09-0666. [DOI] [PubMed] [Google Scholar]
  • 10.Kwee SA, DeGrado TR, Talbot JN, et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–428. doi: 10.1053/j.semnuclmed.2007.07.003. [DOI] [PubMed] [Google Scholar]
  • 11.Behesthi M, Haim S, Zakavi R, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833–840. doi: 10.2967/jnumed.112.110148. [DOI] [PubMed] [Google Scholar]
  • 12.Marzola MC, Chondrogiannis S, Ferretti A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med. 2013;38:e26–e28. doi: 10.1097/RLU.0b013e318266cc38. [DOI] [PubMed] [Google Scholar]

Articles from Nuclear Medicine and Molecular Imaging are provided here courtesy of Springer

RESOURCES